-
Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
-
Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
-
Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
-
Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test detects 76% of systemic cancers at 97% specificity.
ESICM Symposium: ‘NETs: Casting a new light on sepsis management’ – Video
- Share
- Tweet
- Share on Facebook
- Share
A recording of Volition’s symposium from ESICM 2024, titled ‘NETs: Casting a new light on sepsis management’.
Chaired by Prof. Djillali Annene, Professor of Medicine, University Paris Saclay-UVSQ, France, and featuring presentations from:
- Dr. Caroline Neumann, Senior Consultant in Intensive Care Medicine, Jena University Hospital, Germany,
- Dr. Andrew Retter, Clinical Lead in Critical Care Medicine, ECMO and Thrombosis, and CMO at Volition
- Terry Kelly, PhD, Chief Innovation Officer at Volition
View the posters presented at ESICM 2024:
- Neumann et al: Clinical utility of the Nucleosome levels in septic Acute Kidney Injury: improved classification and targeted intervention?
- Berman et al: Nanopore sequencing to elucidate the origins of circulating DNA during extracorporeal membrane oxygenation.
Subscribe for Volition product updates.
Or, click here for Investor Updates and press releases.
"*" indicates required fields